- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Science & technology | COX-2 inhibitors VIOXX NATION THE RISKS AND BENEFITS OF NEW ANTI-INFLAMMATORY DRUGS FOR drugs that are meant to relieve pain, COX-2 inhibitors—a new class of
medicines to treat arthritis and other inflammatory diseases—are causing plenty of discomfort these days. Merck, an American drug company, withdrew Vioxx, its $3 billion-a-year blockbuster,
from the market in September after clinical trials revealed it doubled the risk of heart disease. The safety of several other COX-2 inhibitors, among them Celebrex and Bextra made by Pfizer,
the world's largest drug company, has also been questioned. Next month America's Food and Drug Administration (FDA) will hold a public hearing to look at the risk and benefits of
these drugs. This article appeared in the Science & technology section of the print edition under the headline “Vioxx nation” ------------------------- SCIENCE & TECHNOLOGY January
29th 2005 * →Foundation * →Vioxx nation * →Hot models * →The Richard Casement internship * →Correction: Sir Harry Kroto FROM THE JANUARY 29TH 2005 EDITION Discover stories from this section
and more in the list of contents ⇒Explore the edition
